Blood: sutimlimab therapy improves severe hemolytic anemia in cold agglutinin disease

Condensation pigment is a difficult to treat the disease itself immune hemolytic anemia, a high concentration of circulating immunoglobulin M autoantibodies ( agglutinin ) on erythrocytes "I" due to antigen binding, the major cause of vascular hemolysis

Condensation pigment is a difficult to treat the disease itself immune hemolytic anemia, a high concentration of circulating immune globulin immune M autoantibodies ( agglutinin ) on erythrocytes "I" antigen-binding induced, resulting in major vascular hemolysis

Cold agglutinin induces extravascular hemolysis due to complement-mediated conditioning

Cold agglutinin induces extravascular hemolysis due to complement-mediated conditioning Cold agglutinin induces extravascular hemolysis due to complement-mediated conditioning Cold agglutinin induces extravascular hemolysis due to complement-mediated conditioning

In a first human clinical trial reported in Blood , the investigational drug sutimlimab appeared to be very effective in the treatment of cold agglutinin disease, a rare chronic blood disease for which there is currently no approved treatment

Blood Blood

In this study , sutimlimab is a specific C1s inhibitor that quickly prevented the destruction of red blood cells, increased hemoglobin levels, eliminated the patient's need for blood transfusion, and did not cause serious adverse reactions

Sutimlimab is a specific C1s inhibitor that quickly prevents the destruction of red blood cells, increases hemoglobin levels, eliminates the need for blood transfusions, and does not cause serious adverse reactions

Manage FDA

The study included 10 patients aged 56-76

In these responding patients, within the first week of treatment with the full dose of threotide monoclonal antibody, the destruction of red blood cells ceased, and the patient's hemoglobin level increased significantly

Sutimlimab quickly normalizes bilirubin levels and increases hemoglobin levels

Sutimlimab quickly normalizes bilirubin levels and increases hemoglobin levels

Condensin-mediated complement attacks donor red blood cells in the patient's blood circulation, and the clinical benefit may be short-lived

In this study, sutimlimab was well tolerated and induced a clinically significant increase in hemoglobin levels, even in patients with multiple previous treatment periods, eliminating the need for blood transfusions

Based on these data, sutimlimab was awarded a breakthrough therapy for this disease by the US Food and Drug Administration

Article reference: Ulrich Jäger, Shirley D'Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C.

Leave a message here